NasdaqGS:CNTABiotechs
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After Its 192% One-Year Surge?
If you are wondering whether Centessa Pharmaceuticals at around US$39.42 is still offering value after its surge, you are asking the right question for this stock.
The share price has delivered a 66.4% return year to date and 192.0% over the last year, with the 3 year return described as very large, even though the last 30 days have seen a small 0.8% decline and the last week has been flat at 0.0%.
Recent coverage has focused on Centessa Pharmaceuticals as a higher growth biotech name, and...